Exelixis Inc. Stock
Exelixis Inc. Stock
A loss of -2.600% shows a downward development for Exelixis Inc..
The stock is one of the favorites of our community with 36 Buy predictions and 1 Sell predictions.
As a result the target price of 40 € shows a slightly positive potential of 5.49% compared to the current price of 37.92 € for Exelixis Inc..
Criterium "Worthwhile Investment for the next years" is seen as the biggest plus for Exelixis Inc. stock. Negative votes have not been in the majority for any criteria for this stock
Pros and Cons of Exelixis Inc. in the next few years
Pros
?
B****
?
M***** P*******
?
G***** c******* t* c**********
Cons
?
C******** o* t** e**********
?
S********** s********
?
W********* I********* f** t** n*** y****
Tell us your opinion to access the 'Wisdom of the Crowds'
Performance of Exelixis Inc. vs. its peers
| Security | Change(%) | 1w | 1m | 1y | YTD | 3y | 5y |
|---|---|---|---|---|---|---|---|
| Exelixis Inc. | -2.600% | 0.158% | 7.088% | 6.787% | -1.558% | 150.033% | 93.095% |
| Ironwood Pharmaceuticals | 0.000% | 11.047% | 28.188% | 5.525% | 43.609% | -64.003% | -58.251% |
| Novocure Ltd | 0.380% | -7.870% | 6.809% | -53.443% | 3.794% | -86.440% | -91.518% |
| Iovance Biotherapeutics Inc. | 4.280% | -3.379% | 6.722% | -63.598% | -14.397% | -65.579% | -95.196% |
Comments
Exelixis (NASDAQ:EXEL) had its "buy" rating reaffirmed by analysts at HC Wainwright.
Show more
Ratings data for EXEL provided by MarketBeat
Exelixis (NASDAQ:EXEL) was downgraded by analysts at Bank of America Corporation from a "neutral" rating to an "underperform" rating. They now have a $41.00 price target on the stock.
Show more
Ratings data for EXEL provided by MarketBeat
Exelixis (NASDAQ:EXEL) was upgraded by analysts at Wall Street Zen from a "buy" rating to a "strong-buy" rating.
Show more
Ratings data for EXEL provided by MarketBeat
News
2 Healthcare Stocks to Buy for 2026 and Beyond
The healthcare sector underperformed broader equities in 2025, but that shouldn't deter investors. Many companies in the industry performed relatively well and appear to be solid buy-and-hold
The Ultimate Biotech Stock to Buy With $50 Right Now
Finding great biotech stocks to invest in at a price point of $50 per share (or less) isn't easy. There are plenty of companies in the industry trading for far less money than that, but they tend to
Prediction: These 2 Under-the-Radar Stocks Could Beat the Market in the Next 5 Years
Every investor wants to outperform the market, but it's a challenging feat to achieve. That's why few manage to do it consistently over long periods. What's the best approach to take? Day trading is